{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:07:33Z","timestamp":1778616453259,"version":"3.51.4"},"reference-count":75,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Regione Campania POR Campania","award":["2014\/2020 CUPB63C22001270002 (DGR n. 504 del 10.11.2021)"],"award-info":[{"award-number":["2014\/2020 CUPB63C22001270002 (DGR n. 504 del 10.11.2021)"]}]},{"name":"Domp\u00e8 farmaceutici","award":["2014\/2020 CUPB63C22001270002 (DGR n. 504 del 10.11.2021)"],"award-info":[{"award-number":["2014\/2020 CUPB63C22001270002 (DGR n. 504 del 10.11.2021)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Background: Accelerating recovery and preventing the progression to more severe outcomes for patients with coronavirus disease 2019 (COVID-19) is of paramount importance. Non-steroidal anti-inflammatory agents (NSAIDs) have been widely adopted in the international recommendations for non-severe COVID-19 management. Among NSAIDs, evidence about the efficacy of ketoprofen lysin salt (KLS) in the treatment of non-severe COVID-19 has not been reported. Methods: This retrospective study compared the outcomes of 120 patients with mild to moderate COVID-19 treated at home with KLS between March 2021 and May 2023 compared with the outcomes of 165 patients who received corticosteroids. The outcomes included hospitalization, the need for oxygen supplementation, clinical recovery from acute COVID-19, and time to negative swabs. Results: Symptoms persisted in a lower percentage of patients in the KLS group compared to the corticosteroids group (p &lt; 0.0001) and for a shorter period (p = 0.046). We found 6 patients (5%) in the KLS group were hospitalized compared to 45 (27%) in the corticosteroids group (p &lt; 0.001). A higher percentage of patients in the corticosteroids group require oxygen administration (p &lt; 0.001). In addition, patients taking corticosteroids showed a longer viral shedding period compared to those taking KLS (p = 0.004). A final multivariate analysis suggests that KLS might reduce hospitalization risk, the need for oxygen supplementation, and the persistence of post-COVID-19 symptoms when compared to an oral corticosteroid after adjusting for significant co-variables. Conclusions: KLS might have a positive effect on clinical recovery in non-severe COVID-19 patients. A comparison with other NSAIDs in terms of difference in efficacy and safety should be investigated in further trials.<\/jats:p>","DOI":"10.3390\/pharmacy13030065","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:35:13Z","timestamp":1746185713000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ketoprofen Lysine Salt Versus Corticosteroids in Early Outpatient Management of Mild and Moderate COVID-19: A Retrospective Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Domenica Francesca","family":"Mariniello","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2902-3558","authenticated-orcid":false,"given":"Raffaella","family":"Pagliaro","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"D\u2019Agnano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Schiattarella","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-5901","authenticated-orcid":false,"given":"Andrea","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/ijbs.45053","article-title":"SARS-CoV-2: An Emerging Coronavirus that Causes a Global Threat","volume":"16","author":"Zheng","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ortiz-Prado, E., Simba\u00f1a-Rivera, K., Barreno, L.G., Rubio-Neira, M., Guaman, L.P., Kyriakidis, N.C., Muslin, C., Jaramillo, A.M.G., Barba-Ostria, C., and Cevallos-Robalino, D. (2020). Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn. Microbiol. Infect. Dis., 98.","DOI":"10.1016\/j.diagmicrobio.2020.115094"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e07112","DOI":"10.1016\/j.heliyon.2021.e07112","article-title":"Remarkable vessel enlargement within lung consolidation in COVID-19 compared to AH1N1 pneumonia: A retrospective study in Italy","volume":"7","author":"Bianco","year":"2021","journal-title":"Heliyon"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: A storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bianco, A., Conte, S., Mariniello, D.F., Allocca, V., Matera, M.G., D\u2019agnano, V., Lanata, L., Cazzola, M., and Perrotta, F. (2022). Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy. Life, 12.","DOI":"10.3390\/life12111824"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40264-021-01089-5","article-title":"NSAIDs and COVID-19: A Systematic Review and Meta-analysis","volume":"44","author":"Moore","year":"2021","journal-title":"Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/jpc.15159","article-title":"Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19?","volume":"56","author":"Vosu","year":"2020","journal-title":"J. Paediatr. Child. Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","article-title":"ACE2: The Major Cell Entry Receptor for SARS-CoV-2","volume":"198","author":"Scialo","year":"2020","journal-title":"Lung"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","article-title":"Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study","volume":"10","author":"Alqahtani","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2020-219517","article-title":"Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts","volume":"80","author":"Wong","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101373","DOI":"10.1016\/j.eclinm.2022.101373","article-title":"Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis","volume":"46","author":"Zhou","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41533-022-00300-z","article-title":"The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19","volume":"32","author":"Kushner","year":"2022","journal-title":"npj Prim. Care Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"de Bruin, N., Schneider, A.-K., Reus, P., Talmon, S., Ciesek, S., Bojkova, D., Cinatl, J., Lodhi, I., Charlesworth, B., and Sinclair, S. (2022). Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031049"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00003088-199019030-00004","article-title":"Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers","volume":"19","author":"Jamali","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/QCO.0000000000001024","article-title":"NSAIDs for early management of acute respiratory infections","volume":"37","author":"Bassetti","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.bcp.2004.07.015","article-title":"Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen","volume":"68","author":"Levoin","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.15586\/v51i6.918","article-title":"Clinical use of ketoprofen lysine salt: A reappraisal in adolescents with acute respiratory infections","volume":"51","author":"Marseglia","year":"2023","journal-title":"Allergol. Immunopathol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kuczy\u0144ska, J., and Nieradko-Iwanicka, B. (2021). Future prospects of ketoprofen in improving the safety of the gastric mucosa. Biomed. Pharmacother., 139.","DOI":"10.1016\/j.biopha.2021.111608"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Novelli, R., Aramini, A., Boccella, S., Bagnasco, M., Cattani, F., Ferrari, M.P., Goisis, G., Minnella, E.M., Allegretti, M., and Pace, V. (2022). Ketoprofen lysine salt has a better gastrointestinal and renal tolerability than ketoprofen acid: A comparative tolerability study in the Beagle dog. Biomed. Pharmacother., 153.","DOI":"10.1016\/j.biopha.2022.113336"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jps.2600790909","article-title":"Drug Assay in Ground Tissues: Example of Ketoprofen Diffusion into Tonsillar Tissue","volume":"79","author":"Lapicque","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mariniello, D.F., Allocca, V., D\u2019agnano, V., Villaro, R., Lanata, L., Bagnasco, M., Aronne, L., Bianco, A., and Perrotta, F. (2022). Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?. Molecules, 27.","DOI":"10.3390\/molecules27248919"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"The RECOVERY Collaborative Group (2021). Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Scial\u00f2, F., Mariniello, D.F., Nigro, E., Komici, K., Allocca, V., Bianco, A., Perrotta, F., and D\u2019agnano, V. (2022). Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19. Life, 12.","DOI":"10.3390\/life12111924"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.arbres.2021.11.007","article-title":"Corticosteroids and Delayed Conversion of SARS-CoV-2 RNA Nasopharyngeal Swabs in Hospitalized Patients with COVID-19 Pneumonia","volume":"58","author":"Parrella","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MCP.0000000000000967","article-title":"Current challenges and perspectives in lung cancer care during COVID-19 waves","volume":"29","author":"Mariniello","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"World Health Organization (2020). Clinical Management of COVID-19: Interim Guidance, 27 May 2020, World Health Organization. Document Number: WHO\/2019-nCoV\/clinical\/2020.5.","DOI":"10.15557\/PiMR.2020.0004"},{"key":"ref_30","first-page":"1824","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s40121-021-00487-7","article-title":"Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)","volume":"10","author":"Bassetti","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2023.8823","article-title":"Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection","volume":"329","author":"Thaweethai","year":"2023","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"ANalbandian","year":"2021","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJM199106133242407","article-title":"Nonsteroidal antiinflammatory drugs--differences and similarities","volume":"324","author":"Brooks","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"FitzGerald, Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e21666","DOI":"10.1096\/fj.202100540R","article-title":"High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients","volume":"35","author":"Archambault","year":"2021","journal-title":"FASEB J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3906\/sag-2006-96","article-title":"The assessment of the serum levels of TWEAK and prostaglandin F2\u03b1 in COVID-19","volume":"50","author":"Sehmen","year":"2020","journal-title":"Turk. J. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.7883\/yoken.JJID.2021.020","article-title":"Assessment of Galectin-1, Galectin-3, and Prostaglandin E2 Levels in Patients with COVID-19","volume":"74","author":"Kazancioglu","year":"2021","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hong, W., Chen, Y., You, K., Tan, S., Wu, F., Tao, J., Chen, X., Zhang, J., Xiong, Y., and Yuan, F. (2020). Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.561674"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.4049\/jimmunol.2001325","article-title":"Longitudinal Peripheral Blood Transcriptional Analysis Reveals Molecular Signatures of Disease Progression in COVID-19 Patients","volume":"206","author":"Yan","year":"2021","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.abf3192","article-title":"Bioactive lipids in antiviral immunity","volume":"371","author":"Theken","year":"2021","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00014-21","DOI":"10.1128\/JVI.00014-21","article-title":"Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection","volume":"95","author":"Chen","year":"2021","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gimeno, A., Mestres-Truyol, J., Ojeda-Montes, M.J., Macip, G., Saldivar-Espinoza, B., Cereto-Massagu\u00e9, A., Pujadas, G., and Garcia-Vallv\u00e9, S. (2020). Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113793"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xu, T., Gao, X., Wu, Z., Selinger, D.W., and Zhou, Z. (2020). Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo. bioRxiv.","DOI":"10.1101\/2020.04.01.017624"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sisakht, M., Solhjoo, A., Mahmoodzadeh, A., Fathalipour, M., Kabiri, M., and Sakhteman, A. (2021). Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19. Comput. Biol. Med., 136.","DOI":"10.1016\/j.compbiomed.2021.104686"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S1473-3099(22)00433-9","article-title":"Home as the new frontier for the treatment of COVID-19: The case for anti-inflammatory agents","volume":"23","author":"Perico","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6878","DOI":"10.4049\/jimmunol.175.10.6878","article-title":"Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection","volume":"175","author":"Carey","year":"2005","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100941","DOI":"10.1016\/j.eclinm.2021.100941","article-title":"A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study","volume":"37","author":"Suter","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bcp.12938","article-title":"Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: Data from drug-induced liver injury case-control study in Italy","volume":"82","author":"Donati","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","first-page":"33","article-title":"Ketoprofen (19.583 R.P.) (2-(3-benzoylphenyl)-propionic acid). Main pharmacological properties--outline of toxicological and pharmacokinetic data","volume":"1976","author":"Julou","year":"1976","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"ref_54","unstructured":"Scaglione, F. (2022). Utilizzo dei FANS nelle infezioni virali respiratorie, incluso COVID 19. Focus su ketoprofene sale di lisina. Clin. Pract."},{"key":"ref_55","first-page":"61","article-title":"The pharmacology of benoxaprofen with particular to effects on lipoxygenase product formation","volume":"5","author":"Dawson","year":"1982","journal-title":"Eur. J. Rheumatol. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Graziosi, A., Senatore, M., Gazzaniga, G., Agliardi, S., Pani, A., and Scaglione, F. (2025). Ketoprofen Lysine Salt vs. Ketoprofen Acid: Assessing the Evidence for Enhanced Safety and Efficacy. Life, 15.","DOI":"10.3390\/life15040659"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/jcp.26102","article-title":"Differential protein modulation by ketoprofen and ibuprofen underlines different cellular response by gastric epithelium","volume":"233","author":"Brandolini","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00003088-200645070-00008","article-title":"Cerebrospinal fluid distribution of ketoprofen after intravenous administration in young children","volume":"45","author":"Mannila","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","first-page":"387","article-title":"Experimental assessment of some pharmacodynamic features of ketoprofen lysine. Pain relief activity, antipyretic effects, anti-inflammatory activity, anti-platelet aggregation activity and interference with the biosynthesis of prostaglandins","volume":"137","author":"Marmo","year":"1980","journal-title":"Arch. Sci. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8896536","DOI":"10.1155\/2020\/8896536","article-title":"Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways","volume":"2020","author":"Nigro","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41366-022-01071-w","article-title":"Visceral fat inflammation and fat embolism are associated with lung\u2019s lipidic hyaline membranes in subjects with COVID-19","volume":"46","author":"Colleluori","year":"2022","journal-title":"Int. J. Obes."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Perrotta, F., Scial\u00f2, F., Mallardo, M., Signoriello, G., D\u2019agnano, V., Bianco, A., Daniele, A., and Nigro, E. (2023). Adiponectin, Leptin, and Resistin Are Dysregulated in Patients Infected by SARS-CoV-2. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021131"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"926968","DOI":"10.1155\/2012\/926968","article-title":"PGI2 as a regulator of inflammatory diseases","volume":"2012","author":"Dorris","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9343(01)00838-5","article-title":"Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin","volume":"111","author":"Rosenstein","year":"2001","journal-title":"Am. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Boccia, M., Aronne, L., Celia, B., Mazzeo, G., Ceparano, M., D\u2019Agnano, V., Parrella, R., Valente, T., Bianco, A., and Perrotta, F. (2020). COVID-19 and coagulative axis: Review of emerging aspects in a novel disease. Monaldi. Arch. Chest. Dis., 90.","DOI":"10.4081\/monaldi.2020.1300"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jacbts.2020.12.009","article-title":"Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients","volume":"6","author":"Canzano","year":"2021","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Komici, K., Bianco, A., Perrotta, F., Iacono, A.D., Bencivenga, L., D\u2019Agnano, V., Rocca, A., Bianco, A., Rengo, G., and Guerra, G. (2021). Clinical Characteristics, Exercise Capacity and Pulmonary Function in Post-COVID-19 Competitive Athletes. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143053"},{"key":"ref_68","unstructured":"National Institutes of Health (NIH) (2024, November 02). Therapeutic Management of Hospitalized Adults with COVID-19. Available online: https:\/\/adsp.nm.org\/uploads\/1\/4\/3\/0\/143064172\/nih_hosp_adult_guideline.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1172\/JCI143331","article-title":"Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome","volume":"130","author":"Matthay","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Shuto, H., Komiya, K., Yamasue, M., Uchida, S., Ogura, T., Mukae, H., Tateda, K., Hiramatsu, K., and Kadota, J.-I. (2020). A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-78054-2"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.imj.2022.09.004","article-title":"Effect of methylprednisolone therapy on hospital stay and viral clearance in patients with moderate COVID-19","volume":"1","author":"Li","year":"2022","journal-title":"Infect. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"106236","DOI":"10.1016\/j.rmed.2020.106236","article-title":"Matera, Guidance on nebulization during the current COVID-19 pandemic","volume":"176","author":"Cazzola","year":"2021","journal-title":"Respir. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e068060","DOI":"10.1136\/bmj-2021-068060","article-title":"Inhaled and intranasal ciclesonide for the treatment of COVID-19 in adult outpatients: CONTAIN phase II randomised controlled trial","volume":"375","author":"Ezer","year":"2021","journal-title":"BMJ"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/3\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:25:59Z","timestamp":1760030759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/3\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["pharmacy13030065"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13030065","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}